Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clene Inc
(NQ:
CLNN
)
0.4254
+0.0004 (+0.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
241,363
Open
0.4300
Bid (Size)
0.4200 (2)
Ask (Size)
0.4300 (79)
Prev. Close
0.4250
Today's Range
0.4200 - 0.4310
52wk Range
0.2500 - 1.220
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
March 26, 2024
Penny stocks are incredibly risky. However, if you can handle the heat, these ideas might be worth your while.
Via
InvestorPlace
Clene Inc. (NASDAQ: CLNN) Announces Operational Highlights for Lead Therapeutic Candidate for ALS and MS
March 26, 2024
Via
Investor Brand Network
Performance
YTD
+44.69%
+44.69%
1 Month
+0.09%
+0.09%
3 Month
+51.93%
+51.93%
6 Month
-14.92%
-14.92%
1 Year
-61.33%
-61.33%
More News
Read More
New Study Leverages Real-World Data to Assess Differences in Parkinson’s Progression
March 25, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) Work in Nanotechnology Highlighted in ‘First in Human’ Podcast
March 19, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)
March 15, 2024
Via
Investor Brand Network
Breaking Down Clene: 4 Analysts Share Their Views
March 13, 2024
Via
Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights
March 13, 2024
Via
Investor Brand Network
Exposures
Product Safety
Clene: Q4 Earnings Insights
March 13, 2024
Via
Benzinga
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference
March 07, 2024
Via
Investor Brand Network
A Comparison Between ALS, Parkinson’s Disease
March 01, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum
February 29, 2024
Via
Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
February 05, 2024
Via
News Direct
BioMedNewsBreaks — Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle
February 27, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data
February 22, 2024
Via
Investor Brand Network
BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients
February 20, 2024
Via
Investor Brand Network
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 14, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 13, 2024
Via
Benzinga
Clene Inc. (NASDAQ: CLNN) Revolutionizes Approach to Restore Neuronal Health in Neurodegenerative Disease with CNM-Au8(R)
February 13, 2024
Via
Investor Brand Network
7 Underappreciated Penny Stocks That Pack a Wallop
February 12, 2024
Via
InvestorPlace
New MRI Procedure Eases Multiple Sclerosis Diagnosis
February 12, 2024
Via
Investor Brand Network
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) CEO Discusses MS Trial Results During Latest Proactive Interview
February 06, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Reports ‘Unprecedented,’ Statistically Significant Long-Term Clinical Improvements for VISIONARY-MS Trial Participants with Stable Relapsing-Remitting MS
February 06, 2024
Via
Investor Brand Network
Clene Inc. announces positive results from CNM-Au8 results from MS trial
February 05, 2024
Via
TheNewswire.com
BioMedNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Produces ‘Significant and Very Promising Effect’ in Parkinson’s, MS Patients
February 02, 2024
Via
Investor Brand Network
Clene Inc. (NASDAQ: CLNN) Unites Physics, Chemistry, Material Science, and Biology to Address Neurodegenerative Diseases With The Company’s Unique CNM-Au8(R) Pipeline
January 30, 2024
Via
Investor Brand Network
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.